Robert Burns
Chairman of the Board
Elected in: 2017
Born: 1947
Independent in relation to major shareholders: Yes
Robert Burns is a Board Director of Targovax and has been CEO of three companies active in research and development of antibodies (Celldex, Affitech, and 4-Antibody AG). Previously, he has been Chairman of Haemostatix, up until the successful divestment to Ergomed. Robert has previously held leading positions in commercial operations and business development at Ludwig Cancer Research, Oxford Glycosciences, British Biotechnology, Applied bioTechnology, and Corning Incorporated. Robert holds a PhD in chemistry from the University of Birmingham.
Board Committee: Chairman of the Remuneration Committee and member of the Audit Committee.
Holdings in Affibody: 30,338 shares and 40,000 options.
Mathias Uhlén
Board Director
Elected in: 1998 (Affibody AB)
Born: 1954
Independent in relation to major shareholders: Yes
Mathias Uhlén is one of the co-founders of Affibody and Professor in biotechnology at KTH Royal School of Technology and Guest Professor at the Karolinska Institute. He is the Program Director of the Human Protein Atlas (HPA) project, which is financed by the Knut and Alice Wallenberg foundation. Mathias is Chairman of the Board of ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB, MU Bioteknik AB, Antibodypedia AB, Atlas Intressenter AB, A05 Diagnostics AB and ProteomEdge AB.
Holdings in Affibody: 905,719 shares (including companies) and 40,000 options.
Jonathan Knowles
Board Director
Elected in: 2011
Born: 1947
Independent in relation to major shareholders: Yes
Jonathan Knowles is Professor in personalized health at the Finnish Institute for Molecular Medicine at Helsinki University and visiting Professor at the University of Oxford. He is currently Chairman of Faron Pharmaceuticals Oy’s Scientific Advisory Board, Chairman of Genomics England’s Access Review Committee, a Board Member of Immunophotonics Inc., and Caris Life Sciences. In his latest leading position, he was Director of Research at Roche and member of the company group’s scientific committee. Additionally, Jonathan was a Board Director of Genentech for twelve years, and of Chugai for seven years.
Holdings in Affibody: 17,305 shares and 40,000 options.
Jakob Lindberg
Board Director
Elected in: 2011
Born: 1972
Independent in relation to major shareholders: Yes
Jakob Lindberg is Chief Scientific Officer of Oncopeptides and board director of Camurus. He was previously a board member at Atlas Antibodies, Alligator Bioscience, and Oncopeptides. Jakob started his career as an analyst at Merrill Lynch in London and then became a consultant with McKinsey, followed by a period as CEO and co-founder of Cellectricon. Jakob holds a licentiate of medical science in molecular immunology and a MSc degree from the Karolinska Institute, as well as a BA in economics and administration from Stockholm University.
Board Committee: Member of the Remuneration Committee.
Holdings in Affibody: 40,000 options.
José Suárez
Board Director
Elected in: 2020
Born: 1969
Independent in relation to major shareholders: No
José F Suárez was appointed to the board of Affibody in 2020.
José Suárez is a Senior Advisor at Patricia Industries. He has more than 20 years of experience in venture capital and private equity and was Manager at Investor Growth Capital, focusing on infrastructure technologies ranging from semiconductors to hardware systems and software. He is a Board Director of Exagrid Corporation and has previously served on the boards of Acquia Inc., AgJunction Inc., BlueArc Inc., eSilicon Corporation, and Trilliant Networks Inc., among others. José holds a bachelor’s degree in Asian Studies from Dartmouth College.
Board Committee: Member of the Audit and Remuneration Committee.
Holdings in Affibody: 0 shares.
Gillian M Cannon
Board Director
Elected in: 2019
Born: 1963
Independent in relation to major shareholders: Yes
Gillian M Cannon is currently Head of Commercial Innovation at Roivant Sciences, and President of Castle Tech Consulting. She has over 30 years of experience in the pharmaceutical industri and has been in leadership roles at multiple prominent global pharmaceutical companies in a wide range of areas. Most recently, she served as President of North American Operations for UCB Inc, a Belgium based bio-pharmaceutical company. Gillian serves as a Board Director for Edinburgh Innovations, Corcept Therapeutics Inc., and Our Future Health. She is also a member of the Advisory Board for Lumanity, and a member of the Advisory Circle for Newcastle University. She holds a PhD in Health Administration, an MBA (concentration in marketing), and an undergraduate degree in Biochemistry. She is also a lecturer in the Drug Discovery Masters program at Drexel University in Philadelphia, USA.
Holdings in Affibody: 40,000 options.
Camilla Sønderby
Board Director
Elected in: 2021
Born: 1972
Independent in relation to major shareholders: Yes
Camilla Sønderby is currently Board Director at F2G, member of the Novo Advisory Group for Novo Holding, and Industrial Advisor for EQT. She has more than 20 years’ international biopharma leadership experience. Most recently from Takeda, where she headed global portfolio commercialisation and global commercial excellence and was a member of the executive committee. Also, Camilla has held various senior operational and strategic positions at Shire, Abbott (now AbbVie), Roche and Schering Plough, covering Europe, USA and Asia. In addition to working with pharma commercialisation, portfolio strategy and collaborating closely with R&D, she has extensive general management and transformation experience. Camilla began her career as management consultant at McKinsey & Co focused on the healthcare industry.
Holdings in Affibody: 40,000 options.
Anders Martin-Löf
Board Director
Elected in: 2021
Born: 1971
Independent in relation to major shareholders: Yes
Anders Martin-Löf is a Board Director of Cantargia. He has extensive experience as CFO in companies listed on the Stockholm stock exchange and is incoming CFO for BioArctic AB. He has previously been CFO at A3P Biomedical, Oncopeptides, Wilson Therapeutics, and RaySearch Laboratories. He has also been Head of Investor Relations and held various positions in business development at Swedish Orphan Biovitrum. Anders holds an MSc in Engineering Physics from the Royal Institute of Technology, and a BSc in Business Administration and Economics from Stockholm University.
Board Committee: Chairman of the Audit Committee.
Holdings in Affibody: 40,000 options.
Michael Monaghan
Board Director
Employee Representative
Elected in: 2022
Born: 1985
Independent in relation to major shareholders: Yes
Michael Monaghan serves on the Board of Directors as an employee representative. He is currently employed as Business Controller at Affibody AB. He has previous experience in controlling, demand planning, and financial analysis as Finance Manager and Analyst at the Nordic affiliates of Abbott Laboratories, Abbvie, and Mylan. Michael has also worked as R&D Controller and in the R&D department as Portfolio Manager at Swedish Orphan Biovitrum (Sobi). Michael received a BA in Business Administration and German from Towson University.
Holdings in Affibody: 5,000 options.
Anna Maria Sandén
Board Director
Employee Representative
Elected in: 2022
Born: 1968
Independent in relation to major shareholders: Yes
Anna Maria Sandén serves on the Board of Directors as an employee representative. She is currently employed as Head of Process Development at Affibody AB. She has previous experience as Senior Scientific Expert within tech transfers, process validations and regulated commercial production of biologics at the Swedish affiliates of Pfizer and Octapharma, Further, Anna Maria has experience of process development at Biovitrum and the Centre for Cell Therapy at Karolinska Hospital. She holds an MSc in Chemical Engineering and a PhD in Biotechnology from the KTH Royal Institute of Technology, Stockholm.
Holdings in Affibody: 10,000 options.